On October 12, Recursion Pharmaceuticals, Inc. fell 8.02% in regular trading, trading at $4.015 per share with turnover of $47.76 million.

The decline comes amid continued market divergence over the company's restructured collaboration agreement with Tempus AI. Tempus has received a global non-exclusive license to Recursion's proprietary RNA foundation model, while up to $84 million in discretionary payments over two years were replaced with $42 million in committed payments over three years. SEC filings also show Recursion lost the right to terminate the agreement for convenience, raising concerns about financial flexibility.

Adding pressure, recent insider transactions disclosed multiple director sales, including 50,000 shares sold by Borgeson Blake on October 6 at $4.84, further dampening sentiment.

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company that integrates over 50 petabytes of proprietary data through its recursive operating system, creating an iterative loop between wet-lab experiments and dry-lab computational tools to identify, validate, and translate therapeutic insights.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)